AB1188 DYNAMICS OF PAIN SYNDROME DURING 180-DAY TREATMENT WITH UNDENATURED COLLAGEN TYPE II IN COMPARE TO GLUCOSAMINE AND CHONDROITIN COMBINATION
Authors: D. Rekalov, I. Golovach, I. Daniuk, R. Kulynych, T. Tarasenko, I. Bryner
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> OA osteoarthritis is a heterogeneous group of diseases of different etiology with similar biological, morphological, clinical manifestations and consequences, which are based on damage to all articular structures (cartilage, subchondral bone, synovial membrane, ligaments, capsules, periarticular muscles). A key role in the pathogenesis of OA is played by an increase in the catabolic activity of various cytokines, as well as matrix metalloproteinases (MMP) of the cartilage itself. <h3>Objectives</h3> The purpose of the study was to compare the dynamics of pain syndrome (based on Western Ontario McMaster Osteoarthritis Index – WOMAC pain subscale) during 180-day treatment with undenatured collagen type II (UC-II) and glucosamine and chondroitin (G + Ch) combination in patients with Grade II knee OA. <h3>Methods</h3> Patients with Grade II knee OA were investigated. 20 patients were administrated the UC-II during 180-day period, 20 patients took the combination of G + Ch during the same period. WOMAC pain subscale was used to evaluate the effectiveness and was completed before the start of therapy and after 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 90, 120, 150, 180 day of treatment. Visual analog scale (VAS) from 0 to 10 was used for assessment the WOMAC subscale by patient. In this abstract we presented the dynamics of pain during walking and nocturnal pain. <h3>Results</h3> The initial data of pain during walking and nocturnal pain in UC-II group were 6.29±0.37 and 4.35±0.59, after treatment – 2.99±0.37 (-52.46 %, р &lt;0.05) and 1.7±0.41 (-60.92 %, р &lt;0.05). In G + Ch group initial data were 7.05±0.43 and 4.85±0.69, after therapy – 3.85±0.35 (-45.39 %, р &lt;0.05) and 2.85±0.51 (-41.24 %, р &lt;0.05). Comparing groups demonstrated the better results according to decrease of WOMAC pain subscale in the group of UC-II: reduce of pain during walking by 28.76 % and reduce of nocturnal pain by 67.65 % (р &lt;0.05). The analysis of the graph of pain during walking has recorded the beginning of significant pain reducing after 30 day of treatment in both groups (Figure 1). The analysis of the graph of nocturnal pain has showed the beginning of significant pain reducing after 50 day of treatment in both groups. Dynamics of nocturnal pain reducing in the G + Ch group was more unstable with periods of reduced efficiency, while in the UC-II group the dynamics was smooth without fluctuations. <h3>Conclusion</h3> The therapy of Grade II knee OA with UC-II during 180-day demonstrates the benefit in reducing of pain during walking and nocturnal pain in compare to G + Ch combination. The dynamics of nocturnal pain reducing in the UC-II group characterizes by gradual decline without significant fluctuations. <h3>References</h3> [1]Bagchi D., Misner B., Bagchi M. et al. (2002) Effects of orally administered undenatured type II collagen against arthritic inflammatory diseases: a mechanistic exploration. Int. J. Clin. Pharmacol. Res., 22, 101-10. [2]Robinson W.H., Lepus C.M., Wang Q. et al. (2016) Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat. Rev. Rheumatol., 12(10), 580-592. doi:10.1038/nrrheum.2016.136. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.